skip to content
Radiopeptides for Targeted Tumour Therapy and the Kidney Preview this item
ClosePreview this item
Checking...

Radiopeptides for Targeted Tumour Therapy and the Kidney

Author: Marleen Melis
Publisher: Erasmus University Rotterdam 2010-12-16
Edition/Format: Book Book : English
Summary:
textabstractOne of the main causes of morbidity and mortality in the modern world is cancer. Accordingto World Health Organization (WHO) reports the worldwide mortality rate due to malignantneoplasms is 12.5%, but in the Western world this is about 30% in the 45-75 year agegroup. In The Netherlands the prevalence of different types of cancer varies between sexes;amongst men prostate cancer (21%) and amongst women  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Find a copy online

Links to this item

Find a copy in the library

We were unable to get information about libraries that hold this item.

Details

Document Type: Book
All Authors / Contributors: Marleen Melis
ISBN: 978-90-90-25812-6
Language Note: English
Unique Identifier: 6892891649
Awards:

Abstract:

textabstractOne of the main causes of morbidity and mortality in the modern world is cancer. Accordingto World Health Organization (WHO) reports the worldwide mortality rate due to malignantneoplasms is 12.5%, but in the Western world this is about 30% in the 45-75 year agegroup. In The Netherlands the prevalence of different types of cancer varies between sexes;amongst men prostate cancer (21%) and amongst women breast cancer (33%) are the mostfrequently diagnosed types, expressed as percentage of all registered tumour patients. Lung(16% men, 8% women) and colorectal carcinomas (13%) are major cancers as well (The NetherlandsCancer Registry). In this respect the incidence of cancers from neuroendocrine origin,the main tumour type discussed in this thesis, is very low; less than 0.1%. Because of slowprogression of the disease the prevalence is much higher, however.Many different clinical tools are available to detect tumours. Several imaging modalities canbe employed to visualize tumours and their metastases, including radiography using X-rays,ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and nuclearimaging. The latter includes gamma (γ)-radiation, both planar- and single-photon emissioncomputed tomography- (SPECT) imaging and positron (β+) emission tomography (PET). Fortherapy surgery is the first option, followed by (adjuvant) chemotherapy, external beam radiationtherapy (EBRT), radionuclide therapy, or combinations thereof. The ideal situation duringtherapy would be that only, or at least primarily, tumour cells are removed, damaged or killed,while harmful side effects on normal cells and tissues are reduced to a minimum. Any undesirableeffects may be unavoidable though.Over the last decades progress has been achieved concerning specific targeting of tumourcells. This concept is based on the presence of biomarkers expressed only, mainly or in highdensity on malignant cells in comparison to healthy cells. Targeting agents with specific ligand-binding properties to these biomarkers, can be applied as tumour targeting tools fordiagnostic or therapeutic use. Diagnostic imaging is feasible when γ- or β+-emitting radionuclidesor other imaging tags are labelled to tumour-specific antibodies or peptides. Theseantibodies and peptides can have a therapeutic effect as such, but when conjugated with atherapeutic alpha (α)- or beta (β—)-emitting radionuclide or other cytotoxic compound DNAdamage can be induced to destroy tumour cells expressing the biomarkers, while sparinghealthy tissues.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/6892891649> # Radiopeptides for Targeted Tumour Therapy and the Kidney
    a schema:Book, schema:CreativeWork ;
    library:oclcnum "6892891649" ;
    rdfs:comment "949 $l doctoralthesis" ;
    schema:about <http://experiment.worldcat.org/entity/work/data/3984498073#Thing/renal_cancer> ; # renal cancer
    schema:about <http://experiment.worldcat.org/entity/work/data/3984498073#Thing/cancer> ; # cancer
    schema:about <http://experiment.worldcat.org/entity/work/data/3984498073#Thing/urology> ; # urology
    schema:about <http://experiment.worldcat.org/entity/work/data/3984498073#Thing/kidney_tumors> ; # kidney tumors
    schema:about <http://experiment.worldcat.org/entity/work/data/3984498073#Thing/radiopeptides> ; # radiopeptides
    schema:creator <http://experiment.worldcat.org/entity/work/data/3984498073#Person/melis_marleen> ; # Marleen Melis
    schema:datePublished "2010/12/16" ;
    schema:description "textabstractOne of the main causes of morbidity and mortality in the modern world is cancer. Accordingto World Health Organization (WHO) reports the worldwide mortality rate due to malignantneoplasms is 12.5%, but in the Western world this is about 30% in the 45-75 year agegroup. In The Netherlands the prevalence of different types of cancer varies between sexes;amongst men prostate cancer (21%) and amongst women breast cancer (33%) are the mostfrequently diagnosed types, expressed as percentage of all registered tumour patients. Lung(16% men, 8% women) and colorectal carcinomas (13%) are major cancers as well (The NetherlandsCancer Registry). In this respect the incidence of cancers from neuroendocrine origin,the main tumour type discussed in this thesis, is very low; less than 0.1%. Because of slowprogression of the disease the prevalence is much higher, however.Many different clinical tools are available to detect tumours. Several imaging modalities canbe employed to visualize tumours and their metastases, including radiography using X-rays,ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and nuclearimaging. The latter includes gamma (γ)-radiation, both planar- and single-photon emissioncomputed tomography- (SPECT) imaging and positron (β+) emission tomography (PET). Fortherapy surgery is the first option, followed by (adjuvant) chemotherapy, external beam radiationtherapy (EBRT), radionuclide therapy, or combinations thereof. The ideal situation duringtherapy would be that only, or at least primarily, tumour cells are removed, damaged or killed,while harmful side effects on normal cells and tissues are reduced to a minimum. Any undesirableeffects may be unavoidable though.Over the last decades progress has been achieved concerning specific targeting of tumourcells. This concept is based on the presence of biomarkers expressed only, mainly or in highdensity on malignant cells in comparison to healthy cells. Targeting agents with specific ligand-binding properties to these biomarkers, can be applied as tumour targeting tools fordiagnostic or therapeutic use. Diagnostic imaging is feasible when γ- or β+-emitting radionuclidesor other imaging tags are labelled to tumour-specific antibodies or peptides. Theseantibodies and peptides can have a therapeutic effect as such, but when conjugated with atherapeutic alpha (α)- or beta (β—)-emitting radionuclide or other cytotoxic compound DNAdamage can be induced to destroy tumour cells expressing the biomarkers, while sparinghealthy tissues." ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/3984498073> ;
    schema:name "Radiopeptides for Targeted Tumour Therapy and the Kidney" ;
    schema:productID "6892891649" ;
    schema:publication <http://www.worldcat.org/title/-/oclc/#PublicationEvent/erasmus_university_rotterdam2010_12_16> ;
    schema:publisher <http://experiment.worldcat.org/entity/work/data/3984498073#Agent/erasmus_university_rotterdam> ; # Erasmus University Rotterdam
    schema:url <http://hdl.handle.net/1765/21854> ;
    schema:workExample <http://worldcat.org/isbn/978-90-90-25812-6> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/6892891649> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/3984498073#Agent/erasmus_university_rotterdam> # Erasmus University Rotterdam
    a bgn:Agent ;
    schema:name "Erasmus University Rotterdam" ;
    .

<http://hdl.handle.net/1765/21854>
    rdfs:comment "NARCIS" ;
    .

<http://worldcat.org/isbn/978-90-90-25812-6>
    a schema:ProductModel ;
    schema:isbn "978-90-90-25812-6" ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.